ObesityGASOLINNCT02598791
GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake
A study testing IIGI+GIP, IIGI+GLP-1 and OGTT in people with Obesity and Adiposity, run by University Hospital, Gentofte, Copenhagen at 1 site in Denmark.
Trial summary
We aim to delineate the effects of separate and combined infusion of GIP and GLP-1 on food intake, appetite, bone health and fat metabolism in overweight/obese subjects. Read more about this study
- Who is it for?
- Ages 25 to 70 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Obesity, Adiposity, Type 2 Diabetes
- What is being tested?
- IIGI+GIP, IIGI+GLP-1 and OGTT
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 18 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Oct 2015to 20 Jun 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 70 years
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Caucasian men
- Age between 25 and 70 years
- Body mass index (BMI) between 25 and 40 kg/m2
Who cannot join
- Diabetes or prediabetes (defined as glycated haemoglobin (HbA1c) ≥ 43 mmol/mol)
- Anaemia (defined as haemoglobin < 8.3 mmol/l)
- Any gastrointestinal disease that may interfere with the endpoint variables
- Anorexia, bulimia or binge eating disorder
- Allergy or intolerance to ingredients included in the standardised meals
- Tobacco smoking
- Any regular drug treatment that cannot be discontinued for minimum 18 hours
- Any physical or psychological condition that the investigator feels would interfere with trial participation
Trial locations and contacts
1 site in 1 country.
About this study
We aim to delineate the effects of separate and combined infusion of GIP and GLP-1 on food intake, appetite, bone health and fat metabolism in overweight/obese subjects.
Read the detailed description
The gut-derived incretin glucagon-like peptide-1 (GLP-1) is a potent regulator of gastric emptying, appetite and food intake in humans whereas its sister incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), does not seem to have independent effects on these variables in humans. Interestingly, recent data from rodents have shown that concomitant activation of the GIP and the GLP-1 receptor may potentiate the satiety-promoting and body weight-reducing effects of GLP-1. Also, evidence suggests that GIP may be an important mediator of bone remodelling and lipid deposition. The effect of simultaneous activation of the GIP and GLP-1 receptors on appetite, food intake, fat metabolism and bone health has not been thoroughly examined in humans. The aim of this study is to delineate the effects of GIP/GLP-1 receptor co-activation on food intake, mechanisms regulating food intake, fat and bone metabolism in obese subjects.
Material and methods:
The investigators plan to include 18 obese/overweight men without diabetes. The primary endpoint of the study is food intake during continuous intravenous infusions of saline (placebo), GIP, GLP-1 and GIP+GLP-1, respectively. Secondary endpoints includes resting energy expenditure (measured by indirect calorimetry), appetite, satiety and hunger assessments (measured by visual analogue scales), plasma insulin, C-peptide and glucagon secretion, plasma triglycerides, cholesterols, and free fatty acid responses and changes in plasma bone turnover markers.
- Conditions
- Obesity, Adiposity, Type 2 Diabetes
- Being tested
- IIGI+GIP, IIGI+GLP-1, IIGI+NaCl (placebo), OGTT, IIGI+GIP+GLP-1
- Keywords
- incretin hormones, GIP, GLP-1
- Medical subject headings
- Obesity, Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
IIGI+GIPOther
Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia
IIGI+GLP-1Other
glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia
IIGI+NaCl (placebo)Other
i.v. NaCl during isoglycemia
OGTTOther
50 g oral glucose tolerance test
IIGI+GIP+GLP-1Other
i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia
| Study group | Role | What they receive |
|---|---|---|
| IIGI+GIP | Active comparator | 4 hour i.v. infusion of glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemic conditions Receives: Other: IIGI+GIP; Other: IIGI+GLP-1; Other: IIGI+NaCl (placebo); Other: OGTT; Other: IIGI+GIP+GLP-1 |
| IIGI+GLP-1 | Active comparator | 4 hour i.v. infusion of glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemic conditions Receives: Other: IIGI+GIP; Other: IIGI+GLP-1; Other: IIGI+NaCl (placebo); Other: OGTT; Other: IIGI+GIP+GLP-1 |
| IIGI+NaCl (placebo) | Placebo comparator | 4 hour i.v. NaCl (placebo) during isoglycemic conditions Receives: Other: IIGI+GIP; Other: IIGI+GLP-1; Other: IIGI+NaCl (placebo); Other: OGTT; Other: IIGI+GIP+GLP-1 |
| IIGI+GIP+GLP-1 | Active comparator | 4 hour co-infusion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 Receives: Other: IIGI+GIP; Other: IIGI+GLP-1; Other: IIGI+NaCl (placebo); Other: OGTT; Other: IIGI+GIP+GLP-1 |
| 50 g OGTT | Other | 50 g oral glucose tolerance test (OGTT) Receives: Other: IIGI+GIP; Other: IIGI+GLP-1; Other: IIGI+NaCl (placebo); Other: OGTT; Other: IIGI+GIP+GLP-1 |
What is being measured
The primary outcome is the main question the study is designed to answer.
food intake
How much does the participant eat of from the ad libitum meal, measured in gram
Measured: 250-280 min
Secondary outcomes (11)
hunger
feeling of hunger measured on a visual analogue scale
Measured: measured at time 0, 30, 60, 90, 120, 180, 210, 240 min
satiety
feeling of satiety measured on a visual analogue scale
Measured: measured at time 0, 30, 60, 90, 120, 180, 210, 240 min
Fullness
feeling of fullness measured on a visual analogue scale
Measured: measured at time 0, 30, 60, 90, 120, 180, 210, 240 min
Prospective food consumption
Prospective food consumption measured on a visual analogue scale
Measured: measured at time 0, 30, 60, 90, 120, 180, 210, 240 min
resting energy expenditure (REE)
changes in REE measured by a ventilated hood 15 minutes at baseline and 15 minutes at time point 210 min.
Measured: -15 to 0 min. and 210 to 225 min.
Insulin
changes in insulin measured in serum
Measured: -30, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min
C-peptide level
changes in C-peptide level measured in serum
Measured: -30, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min
glucagon levels
changes in glucagon levels measured in plasma
Measured: -30, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min
Cholesterol and FFA
changes in cholesterol (TAG, Total cholesterol and free fatty acid measured in plasma)
Measured: -30, 0, 30, 60, 90, 120, 180, 240 min
C-terminal cross-linked telopeptide of bone collagen (CTX)
changes in level of CTX measured in plasma
Measured: -30, 0, 30, 60, 90, 120, 180, 240 min
procollagen type 1 N-terminal propeptide (P1NP)
changes in level of P1NP measured in plasma
Measured: -30, 0, 30, 60, 90, 120, 180, 240 min
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2015 (estimated)
- Study start1 Oct 2015
- Primary completion20 Jun 2016
- Study completion20 Jun 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 18 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Gentofte, Copenhagen
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Natasha Chidekel Bergmann, University Hospital, Gentofte, Copenhagen
- Investigators
- Natasha C Bergmann, MD, Principal investigator, Center for Diabetesresearch, Gentofte Hospital, University of Copenhagen, Denmark
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02598791
- Sponsor's protocol ID
- H-15008790 (GASOLIN)
- Acronym
- GASOLIN
- Status last verified
- Dec 2018
- First submitted
- 31 Oct 2015
- Last updated
- 6 Dec 2018
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Finan B, Ma T, Ottaway N, Muller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, Hembree J, Raver C, Lockie SH, Smiley DL, Gelfanov V, Yang B, Hofmann S, Bruemmer D, Drucker DJ, Pfluger PT, Perez-Tilve D, Gidda J, Vignati L, Zhang L, Hauptman JB, Lau M, Brecheisen M, Uhles S, Riboulet W, Hainaut E, Sebokova E, Conde-Knape K, Konkar A, DiMarchi RD, Tschop MH. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013 Oct 30;5(209):209ra151. doi: 10.1126/scitranslmed.3007218.
PubMed 24174327Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013 Jun 4;17(6):819-837. doi: 10.1016/j.cmet.2013.04.008. Epub 2013 May 16.
PubMed 23684623Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998 Feb 1;101(3):515-20. doi: 10.1172/JCI990.
PubMed 9449682Nissen A, Christensen M, Knop FK, Vilsboll T, Holst JJ, Hartmann B. Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. J Clin Endocrinol Metab. 2014 Nov;99(11):E2325-9. doi: 10.1210/jc.2014-2547. Epub 2014 Aug 21.
PubMed 25144635Bergmann NC, Lund A, Gasbjerg LS, Jorgensen NR, Jessen L, Hartmann B, Holst JJ, Christensen MB, Vilsboll T, Knop FK. Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. J Clin Endocrinol Metab. 2019 Jul 1;104(7):2953-2960. doi: 10.1210/jc.2019-00008.
PubMed 30848791Bergmann NC, Lund A, Gasbjerg LS, Meessen ECE, Andersen MM, Bergmann S, Hartmann B, Holst JJ, Jessen L, Christensen MB, Vilsboll T, Knop FK. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. Diabetologia. 2019 Apr;62(4):665-675. doi: 10.1007/s00125-018-4810-0. Epub 2019 Jan 25.
PubMed 30683945
Study at a glance
From the registry record, last updated by the sponsor on 6 Dec 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake
- ClinicalTrials.gov ID
- NCT02598791
- Acronym / sponsor ID
- GASOLIN / H-15008790 (GASOLIN)
- Conditions
- Obesity, Adiposity, Type 2 Diabetes
- Keywords
- incretin hormones, GIP, GLP-1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 18 participants (actual)
- Lead sponsor
- University Hospital, Gentofte, CopenhagenUniversity, hospital or other
- Study start
- 1 Oct 2015 (actual)
- Primary completion
- 20 Jun 2016 (actual)
- Study completion
- 20 Jun 2016 (actual)
- First posted
- 6 Nov 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
We aim to delineate the effects of separate and combined infusion of GIP and GLP-1 on food intake, appetite, bone health and fat metabolism in overweight/obese subjects.
Detailed description
The gut-derived incretin glucagon-like peptide-1 (GLP-1) is a potent regulator of gastric emptying, appetite and food intake in humans whereas its sister incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), does not seem to have independent effects on these variables in humans. Interestingly, recent data from rodents have shown that concomitant activation of the GIP and the GLP-1 receptor may potentiate the satiety-promoting and body weight-reducing effects of GLP-1. Also, evidence suggests that GIP may be an important mediator of bone remodelling and lipid deposition. The effect of simultaneous activation of the GIP and GLP-1 receptors on appetite, food intake, fat metabolism and bone health has not been thoroughly examined in humans. The aim of this study is to delineate the effects of GIP/GLP-1 receptor co-activation on food intake, mechanisms regulating food intake, fat and bone metabolism in obese subjects.
Material and methods:
The investigators plan to include 18 obese/overweight men without diabetes. The primary endpoint of the study is food intake during continuous intravenous infusions of saline (placebo), GIP, GLP-1 and GIP+GLP-1, respectively. Secondary endpoints includes resting energy expenditure (measured by indirect calorimetry), appetite, satiety and hunger assessments (measured by visual analogue scales), plasma insulin, C-peptide and glucagon secretion, plasma triglycerides, cholesterols, and free fatty acid responses and changes in plasma bone turnover markers.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| IIGI+GIP | Active comparator | Other: IIGI+GIP, Other: IIGI+GLP-1, Other: IIGI+NaCl (placebo), Other: OGTT, Other: IIGI+GIP+GLP-14 hour i.v. infusion of glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemic conditions |
| IIGI+GLP-1 | Active comparator | Other: IIGI+GIP, Other: IIGI+GLP-1, Other: IIGI+NaCl (placebo), Other: OGTT, Other: IIGI+GIP+GLP-14 hour i.v. infusion of glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemic conditions |
| IIGI+NaCl (placebo) | Placebo comparator | Other: IIGI+GIP, Other: IIGI+GLP-1, Other: IIGI+NaCl (placebo), Other: OGTT, Other: IIGI+GIP+GLP-14 hour i.v. NaCl (placebo) during isoglycemic conditions |
| IIGI+GIP+GLP-1 | Active comparator | Other: IIGI+GIP, Other: IIGI+GLP-1, Other: IIGI+NaCl (placebo), Other: OGTT, Other: IIGI+GIP+GLP-14 hour co-infusion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 |
| 50 g OGTT | Other | Other: IIGI+GIP, Other: IIGI+GLP-1, Other: IIGI+NaCl (placebo), Other: OGTT, Other: IIGI+GIP+GLP-150 g oral glucose tolerance test (OGTT) |
Who may qualify
- Ages
- 25 to 70 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Caucasian men
- Age between 25 and 70 years
- Body mass index (BMI) between 25 and 40 kg/m2
Key exclusion criteria (8 listed)
- Diabetes or prediabetes (defined as glycated haemoglobin (HbA1c) ≥ 43 mmol/mol)
- Anaemia (defined as haemoglobin < 8.3 mmol/l)
- Any gastrointestinal disease that may interfere with the endpoint variables
- Anorexia, bulimia or binge eating disorder
- Allergy or intolerance to ingredients included in the standardised meals
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| IIGI+GIPGlucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia | Other | 50 g OGTT, IIGI+GIP, IIGI+GIP+GLP-1, IIGI+GLP-1, IIGI+NaCl (placebo) |
| IIGI+GLP-1glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia | Other | 50 g OGTT, IIGI+GIP, IIGI+GIP+GLP-1, IIGI+GLP-1, IIGI+NaCl (placebo) |
| IIGI+NaCl (placebo)i.v. NaCl during isoglycemia | Other | 50 g OGTT, IIGI+GIP, IIGI+GIP+GLP-1, IIGI+GLP-1, IIGI+NaCl (placebo) |
| OGTT50 g oral glucose tolerance test | Other | 50 g OGTT, IIGI+GIP, IIGI+GIP+GLP-1, IIGI+GLP-1, IIGI+NaCl (placebo) |
| IIGI+GIP+GLP-1i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia | Other | 50 g OGTT, IIGI+GIP, IIGI+GIP+GLP-1, IIGI+GLP-1, IIGI+NaCl (placebo) |
Primary outcome
food intake
Time frame: 250-280 min
How much does the participant eat of from the ad libitum meal, measured in gram
11 secondary outcomes
hunger
Time frame: measured at time 0, 30, 60, 90, 120, 180, 210, 240 min
satiety
Time frame: measured at time 0, 30, 60, 90, 120, 180, 210, 240 min
Fullness
Time frame: measured at time 0, 30, 60, 90, 120, 180, 210, 240 min
Prospective food consumption
Time frame: measured at time 0, 30, 60, 90, 120, 180, 210, 240 min
resting energy expenditure (REE)
Time frame: -15 to 0 min. and 210 to 225 min.
Insulin
Time frame: -30, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min
C-peptide level
Time frame: -30, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min
glucagon levels
Time frame: -30, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min
Cholesterol and FFA
Time frame: -30, 0, 30, 60, 90, 120, 180, 240 min
C-terminal cross-linked telopeptide of bone collagen (CTX)
Time frame: -30, 0, 30, 60, 90, 120, 180, 240 min
procollagen type 1 N-terminal propeptide (P1NP)
Time frame: -30, 0, 30, 60, 90, 120, 180, 240 min
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Dec 2018.
- Background: PubMed 24174327Finan B, Ma T, Ottaway N, Muller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, Hembree J, Raver C, Lockie SH, Smiley DL, Gelfanov V, Yang B, Hofmann S, Bruemmer D, Drucker DJ, Pfluger PT, Perez-Tilve D, Gidda J, Vignati L, Zhang L, Hauptman JB, Lau M, Brecheisen M, Uhles S, Riboulet W, Hainaut E, Sebokova E, Conde-Knape K, Konkar A, DiMarchi RD, Tschop MH. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013 Oct 30;5(209):209ra151. doi: 10.1126/scitranslmed.3007218.
- Background: PubMed 23684623Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013 Jun 4;17(6):819-837. doi: 10.1016/j.cmet.2013.04.008. Epub 2013 May 16.
- Background: PubMed 9449682Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998 Feb 1;101(3):515-20. doi: 10.1172/JCI990.
- Background: PubMed 25144635Nissen A, Christensen M, Knop FK, Vilsboll T, Holst JJ, Hartmann B. Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. J Clin Endocrinol Metab. 2014 Nov;99(11):E2325-9. doi: 10.1210/jc.2014-2547. Epub 2014 Aug 21.
- Derived from this study: PubMed 30848791Bergmann NC, Lund A, Gasbjerg LS, Jorgensen NR, Jessen L, Hartmann B, Holst JJ, Christensen MB, Vilsboll T, Knop FK. Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. J Clin Endocrinol Metab. 2019 Jul 1;104(7):2953-2960. doi: 10.1210/jc.2019-00008.
- Derived from this study: PubMed 30683945Bergmann NC, Lund A, Gasbjerg LS, Meessen ECE, Andersen MM, Bergmann S, Hartmann B, Holst JJ, Jessen L, Christensen MB, Vilsboll T, Knop FK. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. Diabetologia. 2019 Apr;62(4):665-675. doi: 10.1007/s00125-018-4810-0. Epub 2019 Jan 25.
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Natasha C Bergmann, MD principal investigator
Center for Diabetesresearch, Gentofte Hospital, University of Copenhagen, Denmark
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing IIGI+GIP, IIGI+GLP-1 and OGTT in people with Obesity and Adiposity, run by University Hospital, Gentofte, Copenhagen at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
food intake (time frame: 250-280 min). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02598791, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Dec 2018.